United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Tidal Investments LLC

Tidal Investments LLC cut its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 13.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 9,705 shares of the biotechnology company's stock after selling 1,567 shares during the period. Tidal Investments LLC's holdings in United Therapeutics were worth $3,424,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of UTHR. Newbridge Financial Services Group Inc. acquired a new stake in shares of United Therapeutics during the 4th quarter valued at about $25,000. Dunhill Financial LLC grew its position in shares of United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 50 shares during the period. State of Wyoming acquired a new stake in shares of United Therapeutics during the 4th quarter valued at about $62,000. Millstone Evans Group LLC acquired a new stake in shares of United Therapeutics during the 4th quarter valued at about $67,000. Finally, MassMutual Private Wealth & Trust FSB grew its position in shares of United Therapeutics by 31.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock valued at $85,000 after acquiring an additional 58 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently issued reports on UTHR shares. Wall Street Zen cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Bank of America upgraded United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective on the stock in a report on Monday, April 21st. Wells Fargo & Company reiterated an "equal weight" rating and issued a $314.00 price objective (down from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. JPMorgan Chase & Co. lowered their price objective on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a report on Thursday, May 1st. Finally, Morgan Stanley lifted their price objective on United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a report on Thursday, May 1st. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $392.00.

United Therapeutics Stock Down 0.3%

Shares of United Therapeutics stock traded down $1.07 on Friday, hitting $307.65. 269,594 shares of the company were exchanged, compared to its average volume of 442,728. The stock has a market capitalization of $13.88 billion, a price-to-earnings ratio of 13.51, a price-to-earnings-growth ratio of 0.97 and a beta of 0.58. The company has a 50-day moving average price of $299.63 and a 200 day moving average price of $337.91. United Therapeutics Co. has a 1-year low of $264.33 and a 1-year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping the consensus estimate of $6.29 by $0.34. The business had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.17 EPS. Research analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current year.

Insider Transactions at United Therapeutics

In other news, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the sale, the director now owns 8,480 shares of the company's stock, valued at approximately $2,703,424. The trade was a 22.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, April 17th. The shares were sold at an average price of $283.78, for a total transaction of $3,121,580.00. Following the sale, the executive vice president now directly owns 36,781 shares in the company, valued at approximately $10,437,712.18. The trade was a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 55,500 shares of company stock worth $17,054,780 in the last ninety days. Insiders own 10.30% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.